ArticleBMC microbiology2026
Epidemiological characteristics and antibiotic resistance of pathogens in urinary tract infection in Chengdu 2019-2023, China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe sought to analyze the characteristics of pathogenic bacteria in urinary tract infections (UTIs) samples and to measure their resistance to antibiotics in different period of coronavirus disease 2019 (COVID-19) epidemic.
methodsWe retrospectively analyzed changes in the distribution of pathogenic bacteria in UTIs samples as well as their antimicrobial resistance during 2019-2023. We compared the distribution of these pathogens and their antimicrobial resistance before (1/2019-1/2020), during (2/2020-3/2022), and after (4/2022-12/2023) the COVID-19 pandemic. The results obtained were interpreted with reference to Clinical and Laboratory Standards Institute (CLSI M100, 33rd ed., 2023) and analyzed with WHONET 5.6 software.
resultsFrom 2019 to 2023, a total of 19,038 urine bacterial culture samples, of which 3044 were positive, accounting for 15.99%. Positive cultures were most common in individuals aged ≥ 60 years (accounted for over 50%), and drug-resistant strains were also more commonly found in the elderly (accounted for over 57.49%). The top four most common urinary pathogens were Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis and Enterococcus faecium. Escherichia coli resistance to ampicillin remained highest. During the COVID-19 pandemic, Klebsiella pneumoniae demonstrated higher resistance levels to antimicrobial agents including ceftazidime (15.63%-33.33%-17.31%), aztreonam (25.00%-41.94%-28.85%), and cefepime (28.13%-50.54%-34.62%) compared to pre-pandemic and post-pandemic periods, and Klebsiella pneumoniae exhibited resistance rates exceeding 30% for both ampicillin/sulbactam and cefazolin throughout the study period. Susceptibility rates exceeding 78% were demonstrated in Enterococcus faecalis and Enterococcus faecium toward nitrofurantoin, vancomycin, and linezolid. Furthermore, the proportion of drug-resistant strains of Enterococcus faecalis and Enterococcus faecium increased from 61.36% to 77.14% in the pre-pandemic period to 63.41% and 90.00% in the post-pandemic period, respectively. The increase in the proportion of drug-resistant strains was more pronounced in Enterococcus faecium than in Enterococcus faecalis.
conclusionThe main pathogens of UTIs were Escherichia coli. Changes in UTIs risk and antibiotic resistance may be associated with the COVID-19 pandemic. Meanwhile, we have observed a gradual increase in antibiotic resistance among certain pathogens. Therefore, to ensure optimal therapeutic efficacy, antimicrobial susceptibility testing and bacterial culture should be performed prior to antibiotic administration, thus ensuring rational and effective use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.